BRIDGEWATER, N.J., June 6, 2019 /PRNewswire/ -- Insmed
Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases, today announced that Will Lewis, Chairman and Chief
Executive Officer of Insmed, will present at the Goldman Sachs
40th Annual Global Healthcare Conference in Rancho
Palos Verdes on Thursday, June 13, 2019 at 8:00 a.m.
PDT.
The presentation will be webcast live and can be accessed by
visiting the investor relations section of the company's website at
www.insmed.com. The webcast will be archived for a period of 30
days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is
ARIKAYCE® (amikacin liposome inhalation
suspension), which is approved in the
United States for the treatment of Mycobacterium
avium complex (MAC) lung disease as part of a combination
antibacterial drug regimen for adult patients with limited or no
alternative treatment options. MAC lung disease is a rare and often
chronic infection that can cause irreversible lung damage and can
be fatal. Insmed's earlier-stage clinical pipeline includes
INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase
1 with therapeutic potential in non-cystic fibrosis bronchiectasis
and other inflammatory diseases, and INS1009, an inhaled
formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension.
Contact:
Blaine Davis
Head of Investor Relations and Corporate Communications
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-conference-300862017.html
SOURCE Insmed Incorporated